Genmab drug delivers positive results in rheumatoid arthritis  

2009.08.03
Danish biotech company Genmab and GlaxoSmithKline have announced preliminary results from a phase III study of ofatumumab for the treatment of rheumatoid arthritis
Danish biotech company Genmab and US pharma giant GlaxoSmithKline (GSK) have announced preliminary results from a phase III study of ofatumumab administered intravenously for the treatment of rheumatoid arthritis (RA) in patients who had an inadequate response to methotrexate*. Ofatumumab is also being developed for other indications under a co-development and commercialisation agreement between Genmab and GSK. The news is reported in a press release from Genmab.
 
The study met the primary endpoint, ACR20 at 24 weeks, which indicates a 20 per cent or greater improvement of swollen and tender joints as well as improvement in other disease activity measures.
 
CEO of Genmab Lisa N. Drakeman says: "We have always believed in ofatumumab's potential to make a difference in patients' lives. We are pleased with the results of this study, supporting the further investigation of this antibody's promise in the treatment of RA."
 
Carlo Russo, senior vice president of Biopharm Development, GSK, says: "RA can be a highly debilitating disease. It is encouraging to see the reduction in disease symptoms achieved with intravenous ofatumumab, and we look forward to presenting the full study."
 
Genmab creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. The company's pipeline of fully human antibodies consists of 7 products in clinical development as well as several pre-clinical programmes and disease targets under exploration. Genmab is listed on the OMX Nordic Exchange Copenhagen.
 
* methotrexate is a cytotoxic drug used to treat cancer and arthritis – Ed.
 
Link > Genmab                    

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×